Recent Updates
Recently added Catalysts

Nitric Oxide

Phase 3

Bronchiolitis | Small molecule | Other |Beyond Air, Inc.|Last Updated: Jul 9, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment112
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03053388Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With BronchiolitisPHASE3 COMPLETED 69Mar 5, 2017Apr 28, 2018Jul 9, 201910 Israel
NCT01768884Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With BronchiolitisPHASE1 COMPLETED 43Jan 1, 2013Jan 1, 2016May 4, 20161 Israel
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Hospital Length of Stay (LOS)
12 days

LOS is measured in hours from the time of first treatment dose to the time of physician decision to discharge.

Met-Hemoglobin percentage (MetHb) associated with inhaled NO
21 days
Number of participants with adverse events associated with inhaled NO as a measure of safety and tolerability
5 days
Secondary Endpoints
Clinical score of ≤5 (Modified Tal score).
12 days
Oxygen saturation (SaO2) ≥92% in room air (without oxygen supplementation) sustained for at least 2 hours
12 days
Adverse events and NO-related adverse events including methemoglobinemia and nitrogen dioxide levels.
5 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Group 1 - Nitric Oxide treatmentEXPERIMENTAL• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
Group 2 - Control treatmentACTIVE_COMPARATOR• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
Nitric oxide inhalation + standard treatmentEXPERIMENTALInhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
Standard treatmentPLACEBO_COMPARATORStandard treatment
Interventions
NameTypeDescription
Nitric OxideDRUGNitric Oxide given via inhalation in cycles
Supportive treatmentOTHERSupportive treatment (including oxygen)
PlaceboDRUG -
Unlock Study Design Details
Eligibility Criteria
Age RangeN/A — 12 Months
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: 1. 1\. Pediatric subjects 0-12-months old. a. Including subjects born at ≥28 weeks of gestation. 2. Subjects with acute bronchiolitis requiring in-patient hospitalization expected for 24 hours and more. 3. Clinical score of between 7 to 10 at Screening (without oxygen supple...

Countries:Israel
Unlock Eligibility Criteria